Pneumocystis Jiroveci Enfeksiyonu ve Akciğer Tutulumu

1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new
name (Pneumocystis jiroveci) for Pneumocystis from humans.
Emerg. Infect. Dis. 2002; 6: 891-6.
2. Miller RF. Pneumocystis carinii infection in non AIDS patients. Current Opin. Infec.Dis.1999; 12:371.
3. Stringer JR, Walzer PD. Molecular biology and epidemiology
of Pneumocystis carinii infection in AIDS. AIDS 1996;10:
561-571.
4. Frenkel JK. Pneumocystis. In: Binford CH, Connor DH, (eds).
Pathology of tropical and extraordinary diseases. Washington,
DC: Armed Forces Institute of Pathology; 1976;303-7.
5. Vavra J, Kucera K. Pneumocystis carinii Delanoe: its ultrastructure and ultrastructural affinities. J Protozool.1970;17:
463- 83.
6. Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi
DV. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc. Natl. Acad. Sci. USA. 1989;
86: 8625- 8629.
7. Edman JC, Edman U, Cao M, Lundgren B, Kovacs JA, Santi
DV. Isolation and expression of the Pneumocystis carinii
thymidylate synthase gene. Proc. Natl. Acad. Sci. USA. 1989;
86: 6503- 6507.
8. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin
ML. Ribosomal RNA sequence shows Pneumocystis carinii to
be a member of the fungi. Nature 1988; 11; 334: 519-22.
9. Eriksson, O. E. Pneumocystis carinii, a parasite in lungs of
mammals, referred to a new family and order (Pneumocystidaceae, Pneumocystidales, Ascomycota). Systema Ascomycetum. 1994; 13:165-80.
10. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin
ML. Ribosomal RNA genes of Pneumocystis carinii. J Protozool. 1989; 36: 18-20.
11. Liu Y, Rocourt M, Pan S, Liu C, Leibowitz MJ. Sequence and
variability of 5.8S and 26S rRNA genes of Pneumocystis
carinii. Nucleic acids Res. 1992; 20: 3763- 72.
12. Lin H, Niu MT, Yoganathan T, Buck GA. Characterization of
the rRNA- encoding genes and transcripts, and a group- I self
splicing intron in Pneumocystis carinii. Gene. 1992; 119: 163-
73.
13. Lee CH, Helweg- Larsen J, Lundgren B, Lundgren JD, Tang
X, Jin S, Li B, Bartlett MS, Lu JJ, Olsson M, Luvas SB, Roux
P, Cargnel A, Atzori C, Matos O, SmithJW. Update on
P.carinii f. sp. hominis typing based on nucleotide sequence
variations in the internal transcribed spacer regions of rRNA
genes. J Clin Microbiol. 1998; 36: 734-41.
14. Keeley SP, Stringer JR. Sequences of Pneumocystis carinii f.
sp. hominis strais associated with recurrent pneumonia vary at
multiple loci. J Clin Microbiol. 1997; 35: 2745- 47.
15. Latouche S, Ortona E, Mazars E, Margutti P, Tamburini E,
Siracusano A, Guyot K, Nigou M, Roux P. Biodiversty of
Pneumocystis carinii hominis: typing with different DNA regions. J Clin Microbiol. 1997; 35: 383-87.
16. Latouche S, Poirot JL, Bernard C, Roux P. Study of internal
transcribed spacer and mitochondrial large- subunit genes of
Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus infected
patients during one or several episodes of pneumonia. J Clin
Microbiol. 1997; 35:1687-90.
17. Lu JJ, Bartlett MS, Shaw MM, Queener SF, Smith JW, Ortiz-
Rivera M, Leibowitz MJ, Lee CH. Typing of Pneumocystis
carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA
genes. J Clin Microbiol. 1994; 32: 2904-12.
18. Tsolaki AG, Miller RF, Underwood AP, Banerji S, Wakefield
AE. Genetic diversty at the internal transcribed spacer regions
of the rRNA operon among isolates of Pneumocystis carinii
from AIDS patients with recurrent pneumonia. J. Infect Dis.
1996; 174: 141-156.
19. Tang X, Bartlett MS, Smith JW, Lu JJ, Lee CH. Determination of copy number of rRNA genes in Pneumocystis carinii f.
sp. hominis. J Clin Microbiol. 1998; 36: 2491- 94.
20. Hughes WT. Prologue to AIDS: the recognition of infectious
opportunists. Medicine (Baltimore). 1998; 77: 227-32.
21. Hughes WT. Pneumocystis carinii pneumonia. N Engl J Med.
1977; 297: 1381- 83.
22. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start
of highly active antiretroviral therapy in HIV-1 infection.
Lancet. 1999; 353: 1293- 98.
23. Vargas SL, Ponce CA, Gigliotti F, Ulloa AV, Prieto, Munoz
MP, Hughes WT. Transmission of Pneumocystis carinii DNA
from a patient with P. carinii pneumonia to immunocompetent
contact healt care workers. J Clin Microbiol. 2000;38: 1536-
38.
24. Itatani CA, Marshall GJ. Ultrastructural morphology and
staining characteristic of P.carinii in situ and from B.A.L. J
Parasitol. 1998;74:700-12.
25. Ruffolo JJ. Pneumocystis carinii cell structure. In: Walzer PD,
(ed). Pneumocystis carinii Pneumonia. New York: Marcel
Dekker, 1994; 3-24.
26. Olsson M, Sukura A, Lindberg LA, et al. Detections of Pneumocystis carinii DNA by filtration of air. Scan J Infect Dis.
1996; 28: 279-82.
27. Bartlett MS, Vermund SH. Jacobs RL, et al. Detection of
Pneumocystis carinii DNA in air samples: Likely environmental risk to susceptible persons. J Clin Microbiol. 1997; 35:
2511- 3.
28. Lundgren B, Elvin K, Rothman LP, et al. Transmission of
Pneumocystis carinii from patients to hospital staff. Thorax.
1997;52:422- 4.
29. Rodriguez M, Fishman JA. Prevention of infection due to
Pneumocystis spp. in human immunodeficiency virusnegative immunocompromised patients. Clin Microbiol Rev.
2004;17:770-82.
30. Nevez G, Guyot K, Totet A, Raccurt C, Dei- Cas E. Pulmonary colonisation with Pneumocystis carinii in an immunsupressed HIV negative patient: detection and typing of the fungus by PCR. J Med Microbiology. 2001; 50: 198- 200.
31. Ng V L, Yajko D M, Hadley W K. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997; 10: 401–18.
32. Walzer PD. Pneumocystis carinii- New clinical spectrum? N
England J Med. 1991; 324: 263- 265.
33. Hadley WK, Valerie LNG. Pneumocystis. In: Murray PR,
Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds), Manuel
of Clinical Microbiology, Washington: ASM Pres, 1999. 1200.
34. Hughes W.T. Pneumocystis carinii pneumonia. In: Gorbach
SL, Barlett JG, Blacklow NR (eds), Infectious Diseases.
Philadelphia: W.B. Saunders Co, 1998;601.
35. Walzer PD. Pneumocystis carinii. In: Mandell GL,Bennet JE,
Dolin R, (eds) Principles and Practice of Infectious Diseases.
New York: Churchill Livingstone; 1995. 2475. G. Elbüken
102
36. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in
104 patients with AIDS. Chest. 1987;91:323-7.
37. Chaffey MH, Klein JS, Gamsu G, Blanc P, Golden JA. Radiographic distribution of Pneumocystis carinii pneumonia in patients with AIDS treated with prophylactic inhaled pentamidine. Radiology. 1990; 175:715-9.
38. Crans CA Jr, Boiselle PM. Imaging features of Pneumocystis
carinii pneumonia. Crit Rev Diagn Imaging.1999;40:251-84.
39. Obaji J, Lee-Pack LR, Gutierrez C, Chan CK. The pulmonary
effects of long-term exposure to aerosol pentamidine: a 5-year
surveillance study in HIV-infected patients. Chest.
2003;123:1983-7.
40. Bergin CJ, Wirth RL, Berry GJ, Castellino RA. Pneumocystis
carinii pneumonia: CT and HRCT observations. J Comput Assist Tomogr. 1990;14:756-9.
41. Üner A, Ok ÜZ, Korkmaz M. Pneumocystosis. In: Ozcel MA
(ed). İmmün yetmezlikte önemi artan parazit hastalıkları. İzmir:Türk Parazitoloji Derneği yayın no: 12;1999.1-22.
42. Caliendo AM, Hewitt PL, Allegra JM, Keen A, Ruof KL,
Ferraro MJ. Performance of a PCR Assay for detection of
Pneumocystis carinii from respiratory specimens. J Clin Microbiol. 1998; 36: 979-82.
43. Quist J, Hill AR, Serum lactate dehidrogenase (LDH) in
Pneumocystis carinii pneumonia, tuberculosis, and bacterial
pneumonia. Chest. 1995; 108:415-8.
44. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr,
Merali S. S- adenosylmethionine concentrations in diagnosis
of Pneumocystis carinii pneumonia. Lancet 2003; 361:1267-8.
45. Kim HK, Hughes WT, Feldman S. Studies of morphology and
immunofluorescence of Pneumocystis carinii. Proc Soc Exp
Biol Med. 1972;141:304-9.
46. Lung Parasites Incertae Sedis. Pneumocystis jiroveci
(P.carinii). Carlo Denegri Foundation Web sayfası. (Resim III-III).
47. Kim HK, Hughes WT. Comparison of methods for identification of Pneumocystis carinii in pulmonary aspirates. Am J
Clin Pathol. 1973;60:462-6.
48. Tiley SM, Marriott DJ, Harhness JL. An evaluation of four
methods for the detection of Pneumocystis carinii in clinical
specimens. Pathology. 1994;26: 325-8.
49. Lipschik G,Gill VJ, Lungren JD, Andravis VA, Nelson NA,
Nielsen JO, Ognibene FP, Kovacs JA. Improved diagnosis of
Pneumocystis carinii infection by polymerase chain reaction
on induced sputum and blood. Lancet. 1992;340:203-6.
50. Olsson M, Elvin K, Löfdahl S, Linder E. Detection of Pneumocystis carinii DNA in sputum and bronchoalveolar lavage
samples by polymerase chain reaction. J Clin Microbiol. 1993;
31:221–6.
51. Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG,
Lundgren JD, Lundgren B, Diagnostic use of PCR for detection of Pneumocytis carinii in oral wash samples J Clin Microbiol. 1998;36: 2068-72.
52. Lu JJ, Chen CH, Barlett MS, Smith JW, Beckers PJ, Sieben M.
Comparison of Six Different PCR Methods for Detection of
Pneumocytis carinii. J Clin Microbiol. 1995;33:2785-8.
53. Başoğlu ÖK, İndüklenmiş balgamın tanısal değeri. Toraks
Dergisi. 2001;2:53-61.
54. Yale SH, Limper AH. Pneumocystis carinii pneumoia in
patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc.
1996;71: 5-13.
55. Sepkowitz KA. Opportunistic infections in patients with and
patients without acquired immunodefiency syndrome. Clin Infect Dis. 2002;34:1098- 107.
56. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong
D. Pneumocystis carinii pneumonia among patients without
AIDS at a cancer hospital. JAMA. 1992;267:832-7.
57. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of
sulfamethoxazole and trimethoprim chemoprophylaxis for
Pneumocystis carinii pneumonia in AIDS. JAMA.
1988;259:1185-9.
58. U.S. Public Health Service Task Force on Antipnemocystis
Prophylaxis for Patients with Human Immunodeficiency Virus.
Recommendationsfor prophylaxis against Pneumocystis
carinii pneumonia for adults and adolescents infected with
human immmunodeficiency virus. MMWR 1992;41(RR-4):1-
11.
59. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A
meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med.
1996;156:177-88.
60. Moorman A, Von Bargen JC, Palella FJ, Holmberg SD.
Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic
Syndr Hum Retrovirol. 1998;19:182-8.
61. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA,
Holzman RS, Wormser G, Brettman L, Lange M, Murray HW,
Cunningham-Rundles S. An outbreak of community-acquired
Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431-8.
62. Clumeck N. Primary prophylaxis against opportunistic infections in patients with AIDS. N Engl J Med. 1995;332:739-40.
63. Fishman JA. Prevention of Infection Due to Pneumocystis
carinii. Antimicrob Agent Chemother. 1998;42: 995-1004.
64. Pearson RD, Hewlett EL. Use of pyrimethamine-sulfadoxine
(Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. Ann Intern
Med 1987;106:714-8.
65. Hughes WT. Pneumocystis carinii. In: Mandel GL, Douglas
RG, (eds) Principles and practice of infectious diseases. New
York: Wiley; 1978. 1549.
66. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprimsulfamethoxazole compared with pentamidine for treatment of
Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109:280-7.
67. McLean I, Lucas CR, Mashford ML, Harman PJ. Modified
trimethoprim-sulphamethoxazole doses in Pneumocystis
carinii pneumonia. Lancet. 1987;2:857-8.
68. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW,
Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL.
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med.
1984;100:663-71.
69. Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld
W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell
PC. Trimethoprim-sulfamethoxazole or pentamidine for
Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern
Med. 1986;105:37-44.
70. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions
to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med.
1984;100:495-9.
71. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the
treatment of Pneumocystis carinii pneumonitis in patients with
acquired immunodeficiency syndrome. Rev Infect Dis. 1987;
9:84- 94. Pneumocystis Jiroveci Enfeksiyonu ve Akciğer Tutulumu
103
72. Salamone FR, Cunha BA. Update on pentamidine for the
treatment of Pneumocystis carinii pneumonia. Clin Pharm.
1988;7:501-10.
73. Gonzalez A, Sager PT, Akil B, Rahimtoola SH, Bhandari AK.
Pentamidine-induced torsade de pointes. Am Heart J.
1991;122:1489-92.
74. Quadrel MA, Atkin SH, Jaker MA. Delayed cardiotoxicity
during treatment with intravenous pentamidine: two case reports and a review of the literature. Am Heart J. 1992;
123:1377-9.
75. Waskin H, Stehr-Green JK, Helmick CG, Sattler FR. Risk
factors for hypoglycemia associated with pentamidine therapy
for Pneumocystis pneumonia. JAMA. 1988; 260: 345-7.
76. Salmeron S, Petitpretz P, Katlama C, Herve P, Brivet F,
Simonneau G, Duroux P, Regnier B. Pentamidine and pancreatitis. Ann Intern Med. 1986;105:140- 1.
77. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G,
Benowitz N, Wofsy CB. Oral therapy for Pneumocystis carinii
pneumonia in the acquired immunodeficiency syndrome. A
controlled trial of trimethoprim-sulfamethoxazole versus
trimethoprim-dapsone. N Engl J Med. 1990;323:776-82.
78. Sin DD, Shafran SD. Dapsone- and primaquine-induced
methemoglobinemia in HIV-infected individuals. J Acquir
Immune Defic Syndr Hum Retrovirol. 1996;12:477-81.
79. Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic
infections. Drugs. 1995;50:176-96.
80. Hughes W, Kennedy W, Shenep J, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-P.
carinii activity. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 21-24, 1990; Atlanta. Abstract 861.
81. Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, Lancaster DJ, Stein DS, Palte S,
Rosenbaum D. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity:
a phase I study in human immunodeficiency virus (HIV)-
infected men. J Infect Dis. 1991;163:843-8.
82. Falloon J, Kovacs J, Hughes W, O'Neill D, Polis M, Davey
RT, Jr., Rogers M, LaFon S, Feuerstein I, Lancaster D, et al.
A preliminary evaluation of 566C80 for the treatment of
Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:1534-8.
83. Toma E, Fournier S, Poisson H, et al. Clindamycin/primaquine for P. carinii pneumonia in AIDS. In: Program
and abstracts of the V International Conference on AIDS; June
4-9, 1989; Montreal. Abstract T.B.O.31.
84. Fulton B, Wagstaff AJ, McTavish D. Trimetrexate. A review
of its pharmacodynamic and pharmacokinetic properties and
therapeutic potential in the treatment of Pneumocystis carinii
pneumonia. Drugs. 1995;49:563-76.
85. Sattler FR, Allegra CJ, Verdegem TD, Akil B, Tuazon CU,
Hughlett C, Ogata-Arakaki D, Feinberg J, Shelhamer J, Lane
HC, et al. Trimetrexate-leucovorin dosage evaluation study for
treatment of Pneumocystis carinii pneumonia. J Infect Dis.
1990;161:91-6.
86. Gilman TM; Boylen CT; Sattler FR. Pyrimethaminesulfadiazine for treating Pneumocystis carinii pneumonia and
toxoplasmosis in AIDS. Clin Pharm. 1989;8:84-7.
87. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use,
dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis. 2004;10:1760-5.
88. Pareja JG, Garland R, Kolziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-24.
89. Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adult
patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med.
2004;3:381-97.